Meeting
2024 ASCO Genitourinary Cancers Symposium
WUTSUP-02-II-Neo-Dis-Tis: Investigating the efficacy and safety of neoadjuvant tislelizumab plus disitamab vedotin with adjuvant tislelizumab in upper urinary tract carcinoma—A phase II multi-center study.
Authors
Yige Bao
Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China
Yige Bao , Xinyang Liao , Peng Zhang , Hao Zeng , Jiyan Liu , Qiang Wei
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Clinical Trial Registration Number
ChiCTR2300067836
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr TPS718)
DOI
10.1200/JCO.2024.42.4_suppl.TPS718
Abstract #
TPS718
Poster Bd #
M18
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Preliminary efficacy and safety results from ReBirth: A phase II study of risk-based bladder-sparing therapy for MIBC.
First Author: Yijun Shen
Poster
2022 ASCO Annual Meeting
Primary analysis of MUKDEN 01: A multicenter, single-arm, prospective, phase 2 study of neoadjuvant treatment with pyrotinib and letrozole plus dalpiciclib in triple-positive breast cancer.
First Author: Nan Niu
Poster
2024 ASCO Genitourinary Cancers Symposium
A phase II study of neoadjuvant tislelizumab and axitinib in patients with locally advanced non-metastatic clear cell renal cell carcinoma (accRCC).
First Author: Shun Zhang
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase 2 study of trastuzumab deruxtecan as neoadjuvant treatment for HER2-positive gastric and gastroesophageal junction adenocarcinoma (EPOC2003).
First Author: Daisuke Takahari